NCT01911754

Japanese Pediatric H5N1 Vaccine Study

An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Alachua Government Services, Inc. · Industry
• Sex: All
• Age: 6 Months – 17 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)

Timeline

• Start date: 2013-08-01
• Primary completion: 2013-11-01
• Completion: 2014-04-01
• First posted: 2013-07-30
• Last updated: 2015-10-09

Locations

2 sites across 1 country: Japan